The protein biomarker solution for drug development
Protein biomarkers for better informed drug development
Olink’s current library enables almost 1500 proteins to be rapidly and reliably measured in less than 3µL of blood or other types of clinical sample, providing robust, actionable data for every stage of the drug development process. Our innovative PEA technology, based on DNA-coupled antibody pairs that ensure exceptional specificity in high-multiplex assays, has been widely used in clinical research to identify protein biomarkers and signatures that can predict outcomes and responses, effectively stratify patient populations, and provide crucial new insights into the biology of disease. Many pharmaceutical companies have already integrated Olink into their protein biomarker programs, and we are ready to support the global drug development community across all aspects of the drug development process, from target discovery to post-market surveillance.
Combining Olink protein data with genomics for confident selection of novel drug targets
One rapidly developing approach that shows immense promise for novel drug target discovery, is the combination of protein data with large-scale genetic analysis such as genome wide association (GWAS) studies to identify protein Quantitative Trait Loci (pQTLs). These provide robust connections between a gene variant and the levels of a protein. In particular, cis-pQTLs are variants that are proximal to the gene encoding the protein under study, and when combined with clinical data and analyzed by Mendelian Randomization (MR), these can provide extremely confident identification of proteins that are causal in disease and therefore represent promising new drug targets.
Toward this end, pharmaceutical and clinical researchers have come together to form an independent, collaborative framework for discovery and follow-up of genetic associations with proteins, with the latter data specifically generated using the Olink platform. Led by Dr. Anders Mälarstig from Pfizer and the Karolinska Institute, the SCALLOP consortium has so far generated summary level data on SNP-to-protein level associations from almost 30,000 patients or controls. You can read more about SCALLOP here, and in the short video below, Dr. Mälarstig describes the aims of the consortium and explains why this combination of genomic, proteomic and clinical data is so powerful for drug target identification.
Olink data in publications
- Pratta et al (Incyte Corporation) “A Biomarker Signature to Predict Complete Response to Itacitinib and Corticosteroids in Acute Graft-Versus-Host Disease“.
- Ticau et al (Alnylam Pharmaceuticals) “Neurofilament Light Chain (NfL) as a Potential Biomarker in Hereditary Transthyretin Mediated ( hATTR ) Amyloidosis“
DOWNLOAD THESE POSTERS HERE
Selected scientific articles in the pharmaceutical area citing the use of Olink panels
Olink panels have been cited in almost 300 peer-reviewed publications, in clinical research, translational studies, epidemiological studies and many other application areas. Below is a selection of papers more closely related to drug development studies.
Bissonnette R, Maai C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit D, Usansky H, Denis L, Rao N, Song T, Pavel A and Guttman-Yassky E. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study (2019) British Journal of Dermatology, Doi: 10.1111/bjd.17932
Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini M, Wikstrom K, Essand M, Savoldo B, Hallböök H, Höglund M, Dotti G, Brenner M, Hagberg H and Loskog A. A Phase I/IIa Trial Using CD19-Targeted ThirdGeneration CAR T Cells for Lymphoma and Leukemia. (2018) Clinical Cancer Research, doi: 10.1158/1078-0432.CCR-18-0426
Folkersen L, Fauman E, Sabater-Lleal M, Strawbridge R, Frånberg M, Sennblad B, Baldassarre D, Veglia F, Humphries S, Rauramaa R, de Faire U, Smit A, Giral P, Kurl S, Mannarino E, Enroth S, Johansson Å, Bosdotter Enroth S, Gustafsson S, Lind L, Lindgren C, Morris A, Giedraitis V, Silveira A, Franco-Cereceda A, Tremoli E, IMPROVE study group , Gyllensten U, Ingelsson E, Brunak S, Eriksson P, Ziemek D, Hamsten A and Mälarstig A. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. (2017) PLOS Genetics 13(4), doi.org/10.1371/journal.pgen.1006706
Kim J, Tomalin L, Lee J, Fitz L, Berstein G, Correa-da Rosa J, Garcet S, Lowes M, Valdez H, Wolk R, Suarez-Farinas M and Krueger J. Reduction of inflammatory and cardiovascular proteins in the blood of psoriasis patients; differential responses between tofacitinib and etanercept after 4 weeks of treatment. (2017) Journal of Investigative Dermatology, doi:10.1016/j.jid.2017.08.040A
Kragstrup T, Adams M, Lomholt S, Nielsen M, Heftdal L, Schafer P and Deleuran B. IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis. (2019) Therapeutic Advances in Musculoskeletal Disease, doi.org/10.1177/1759720X19828669
Langer A, Leader A, Kim-Schulze S, Ginzburg Y, Merad M and Glassberg J. Inhaled steroids associated with decreased macrophage markers in nonasthmatic individuals with sickle cell disease in a randomized trial. (2019) Annals of Hematology, doi.org/10.1007/s00277-019-03635-9
Toribio M, Fitch K, Stone L, Zanni M, Loa J, de Filippi C, Sponseller C, Lee H, Grundberg I, Thompson M, Aberg J and Grinspoon S. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. (2018) EBioMedicine, doi.org/10.1016/j.ebiom.2018.08.039
See the complete Olink publications list
Olink White Papers
These articles leverage the wealth of knowledge and experience in our research and development team and present you with technical and application-related information: comparison with other technologies, PEA mechanism, study design, data normalization and more. See all White Papers.
Are you curious to explore further?
If you would like to discuss further with us how Olink’s protein biomarker solutions can provide you with actionable data for better informed decision making across the breadth of your drug development programs, please fill in and submit the simple form below and we will do everything we can to assist you.